Immunohistochemical pattern of protein P21, cyclin D1 and cyclin E in endometrial hyperplasia

Polish Journal of Pathology

Volumn 60, Issue 1, 2009, Pages 19-25

  Brucka, Aleksandra ^a   Bartczak, Piotr ^a   Ratyńska, Marzena ^a   Sporny, Stanislaw ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Carcinogenesis; Cell cycle; Endometrium; HRT; Hyperplasia; Neoplasia; Regulatory proteins

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN E;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CELL PROLIFERATION; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; FEMALE; HORMONE SUBSTITUTION; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CELL PROLIFERATION; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENDOMETRIAL HYPERPLASIA; ENDOMETRIUM; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 69849102448     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Dietel M. The histological diagnosis of endometrial hyperplasia. Is there a need to simplify? Virchows Arch 2001; 439: 604-608.
2. Bergeron C, Nogales FF, Masseroli M, et al. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of simplified working classification for biopsy and curretage specimens. Am J Pathol 1999; 23: 1102-1108.
3. Burton JL, Wells M. Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium. Histopathology 1998; 33: 297-303.
4. Sivridis E, Giatromanolaki A. Prognostic aspects on endometrial hyperplasia and neoplasia. Virchows Arch 2001; 439: 118-126.
5. Sivridis E, Fox H, Buckley CH. Endometrial carcinoma: two or three entities? Int J Gynecol Cancer 1998; 8: 183-188.
6. Horn LC, Bilek K, Schnurrbusch U. Endometrial hyperplasiaS: histology, classification, prognostic significance and therapy. Zentralbl Gynakol 1997; 119: 251-259.
7. Sivridis E. Histological evaluation of the endometrium: from hyperplasia to cancer. Eur J Gynaecol Oncol 1996; 5: 440-442.
8. Dunton CJ, Baak J, Palazzo JP, et al. Use of computerized morphometric analyses of endometrial hyperplasias in the prediction of coexistent cancer. Am J Obstet Gynecol 1996; 174: 1518-1521.
9. Ioachin E. Immunohistochemical tumor markers in endometrial carcinoma. Eur J Gynaecol Oncol 2005; 26: 363-371.
10. Geradts J, Kratzke RA, Crush-Stanton S, et al. Wilde type and mutant retinoblastoma protein in paraffin sections. Mod Pathol 1996; l: 339-347.
11. Grana X, Reedy EP. Cell cycle control in mammalian cells: role of cyclin, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995; 11: 211-219.
12. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
13. Shiozawa T, Nikaido T, Shimizu M, et al. Immunohistochemical analysis of the expression of cdk4 and p16INK4 in human endometrioid-type endometrial carcinoma. Cancer 1997; 80: 2250-2256.
14. Ito K, Sasano H, Yoshida Y, et al. Immunohistochemical study of cyclins D and E and cyclin dpendent kinase (cdk) 2 and 4 in human endometrial carcinoma. Anticancer Res 1998; 18: 1661-1664.
15. Tsuda H, Yamamoto K, Inoue T, et al. The role of p16-cyclin D/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma. Br J Cancer 2000; 82: 675-682.
16. Ekholm SV, Reed SI. Regulation of G1 cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 2000; 12: 676-684.
17. Hussain SP, Harris CC. Molecular epidemiology and carcinogenesis: endogenous and exogenous carcinogens. Mutat Res 2000; 462: 311-322.
18. Broceno C, Wilkie S, Mittnacht S. Rb activation defect in tumour cell lines. Proc Natl Acad Sci 2002; 99: 14200-14205.
19. Grzelakowska-Sztabert B. Punkty kontrolne cyklu komórkowego-czy znamy ich molekularne podłoże. Post Biol Kom 2002; 29: 157-175.
20. Lundberg AS, Weinberg SA. Control of the cell cycle and apoptosis. Eur J Cancer 1999; 35: 531-539.
21. Zetterberg A, Larsson O, Wiman KG. What is the restriction point: Curr Opin Cell Biol 1995; 7: 835-842.
22. Farnham PJ, Slansky JE, Kollmar R. The role of E2F in the mammalian cellcycle. Biochem Biophys Acta 1995; 1155: 125-131.
23. Kubiak JZ. Rak i cykl komórkowy. Post Biol Kom 2001; 28: 297-307.
24. Planas-Silva MD, Weinberg RA. The restriction point and control oc cell proliferation. Curr Opin Cell Biol 1997; 9: 768-772.
25. Leoncini L, Bellan C, Cossu A. Retinoblastoma-related p107 and PRb2/p130 proteins in malignant lymphomas: distinct mechanisms of cell growth control. Clin Cancer Res 1999; 5: 4065-4072.
26. Demetric DJ, Matsumoto S, Hannon GJ. Chromosomal mapping of the genes for the human cell cycle proteins cyclin C (CCNC), cyclin E (CCNE), p21 (CDKN1) and KAP (CDKN3). Cytogenet Cell Genet 1995; 69: 190-192.
27. Powell BL, Staveran van IL, Rooksen P. Association between common polymorphismus in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer. Carcinogenesis 2002; 23: 311-315.
28. Pelikainen MJ, Pekola TT, Ropponen KM. p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation and prognosis. J Clin Pathol 2003; 56: 214-220.
29. Palazzo JP, Mercer WE, Kovatich AJ. Immunohistochemical localization of p21WAF1/CIP1 in normal, hyperplastic and neoplastic uterine tissues. Hum Pathol 1997; 28: 60-66.
30. Barbareschi M, Caffo O, Doglioni C. p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer 1996; 74: 208-215.
31. Planas-Silva MD, Weiberg SA. Estrogen-dependent cyclinE-cdk2 activation through p21 redistribution. Moll Cell Biol 1997; 17: 4059-4069.
32. Jong JS, Diest PJ, Michalides. Cocerted overexpression of the genes encoding p21 and cyclin D1 is associated with growth inhibition and differentiation in various carcinomas. J Clin Pathol 1999; 52: 78-83.
33. Quddus MR, Latkovich P, Castellani WJ. Expression of cyclin D1 in normal, metaplastic, hyperplastic endometrium and endometrioid carcinoma suggest a role in endometrial carcinogenesis. Arch Pathol Lab Med 2002; 126: 459-463.
34. Doennallan R, Chetty R. Cyclin E in human cancers FASEB J 1999; 13: 773-780.
35. Furstenthal L, Kaiser BK, Swanson C. Cyclin E uses cdc6 as a chromatin-associated receptor required for DNA replication. J Cell Biol 2001; 152: 1267-1278.
36. Zarkowska T, Mittnacht S. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin dependent kinases. JBC 1997; 272: 12738-12746.
37. Kato N, Watanabe J, Jobo T. Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance. J Cancer Res Clin Oncol 2003; 129: 222-226.
38. Milde-Langossh K, Bamberger AM, Goemann C. Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters. J Cancer Res Clin Oncol 2001; 127: 537-544.
39. Kim HK, Park IA, Heo DS. Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer. Eur J Surg Ocol 2001; 27: 464-471.
40. Keyomarsi K. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347: 1555-1575.
41. Sutherland RL. Perspective: Cyclin E and prognosis in patients with breast cancer. N Engl J Med 2002; 347: 1546-1548.